What is the ROE (Return on Equity) of Insmed this year?
The ROE of Insmed this year is 2.26 undefined.
Insmed ROE 2024
Insmed ROE
2.26
Ticker
INSM
ISIN
US4576693075
WKN
A1JJA3
In 2024, Insmed's return on equity (ROE) was 2.26, a -141.27% increase from the -5.47 ROE in the previous year.
Insmed Aktienanalyse
What does Insmed do?
Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Insmed's Return on Equity (ROE)
Insmed's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Insmed's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Insmed's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Insmed’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Insmed stock
How has the Return on Equity (ROE) of Insmed developed compared to the previous year?
The ROE of Insmed has increased by -141.27% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Insmed?
A high ROE indicates that Insmed generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Insmed?
A low ROE can indicate that Insmed is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Insmed affect the company?
A change in ROE (Return on Equity) of Insmed can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Insmed?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Insmed?
Some factors that can influence Insmed's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Insmed pay?
Over the past 12 months, Insmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Insmed is expected to pay a dividend of 0 USD.
What is the dividend yield of Insmed?
The current dividend yield of Insmed is .
When does Insmed pay dividends?
Insmed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Insmed?
Insmed paid dividends every year for the past 0 years.
What is the dividend of Insmed?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Insmed located?
Insmed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Insmed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Insmed from 10/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.
When did Insmed pay the last dividend?
The last dividend was paid out on 10/28/2024.
What was the dividend of Insmed in the year 2023?
In the year 2023, Insmed distributed 0 USD as dividends.
In which currency does Insmed pay out the dividend?
The dividends of Insmed are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Insmed
Our stock analysis for Insmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Insmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
